Verrica Pharmaceuticals Q1 revenue rises on YCANTH demand

Verrica Pharmaceuticals

12/05/2026 21:12

Overview

Dermatology therapeutics firm's Q1 revenue rose 46% yr/yr on record demand for YCANTH

Adjusted EPS loss widened yr/yr; no analyst consensus available for comparison

Company launched YCANTH in Japan and advanced Phase 3 common warts trial enrollment

Outlook

Company expects to initiate second Phase 3 trial for YCANTH in US and Japan in mid-2026

Verrica continues preparations for Phase 3 study of VP-315 in basal cell carcinoma

Company sees potential market expansion for YCANTH if Phase 3 common warts program is successful

Result Drivers

YCANTH DEMAND - Co said record demand for YCANTH drove increases in dispensed applicator units and U.S. product revenue

JAPAN LAUNCH - Revenue benefited from YCANTH commercial launch in Japan by partner Torii Pharmaceutical

COMMERCIAL SPEND - Selling, general and administrative expenses increased due to expansion of the sales force

Company press release: ID:nGNX98cwTT

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Adjusted EPS
-$0.41
-$0.38 (2 Analysts)
Q1 Adjusted Net Income
-$8.80 mln
Q1 Net Income
-$9.68 mln
Q1 Income from Operations
-$9.72 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Verrica Pharmaceuticals Inc is $18.00, about 143.2% above its May 11 closing price of $7.40

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)